The ADDRESS-LC trial was designed to assess the potential impact of bezisterim on cognitive impairment/brain fog and fatigue in individuals with Long Covid and is currently recruiting people aged 18-64 diagnosed with Long Covid.
This webinar includes an overview of the trial, the requirements for participation, and details on how to join. Hosted by Solve CEO Emily Taylor, panelists Michael Peluso, MD (Assistant Professor of Medicine, University of California, San Francisco), Penny Markham, PhD (Senior Vice President, BioVie), and Ezra Spier (Creator, LongCovidStudies.net) discuss how the lived experience of patients has informed the development and conduct of the ADDRESS-LC trial and the importance of patient-researcher collaboration.
Learn more about the trial at www.addresslc.com.
Watch the webinar on YouTube here.
View the deck for the webinar here.